Caplacizumab-yhdp (Cablivi®)

Covered: Cablivi (caplacizumab-yhdp) is covered for adults (≥18) with acquired TTP only when initiated inpatient in combination with plasma exchange and concurrent immunosuppressive therapy; it is not covered if these criteria aren't met or if the patient has had >2 aTTP recurrences while on Cablivi. Key requirements: must be prescribed or co‑managed by a hematologist, patient must be on at least one immunosuppressive agent, dosing must begin with an 11 mg IV bolus ≥15 minutes before the first plasma exchange then 11 mg SC after that exchange and 11 mg SC daily thereafter, approval is limited to 2 months and no more than 60 doses after the last plasma exchange.

"FDA-approved Indication: Cablivi is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive..."